AbbVie vs. Bristol Myers Squibb: 2026 Healthcare Valuation

### Session Tape - **ABBV:** $259.93 (-0.64%, -$1.66) - **$BMY+WL:** $61.46 (-1.51%, -$0.94)

## Catalyst Analysis: Fundamental Profile Comparison Market participants assessing pharmaceutical allocations face a valuation divergence between AbbVie and Bristol Myers Squibb. AbbVie commands a $462 billion market capitalization alongside a 71.42% gross margin and a price-to-earnings ratio of 73.96, backed by a trailing twelve-month EPS of $3.54 and a dividend yield of 2.61% ($6.83 distribution). Meanwhile, Bristol Myers Squibb trades at a $127 billion market capitalization with a 66.64% gross margin and a lower P/E ratio of 13.75, supported by a trailing EPS of $4.54 and a 4.02% dividend yield ($2.51 distribution). The valuation contrast highlights distinct growth versus income trade-offs across large-cap healthcare holdings.